Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Journal of Computer-Aided Molecular Design
|
January 13, 2011
Guiding effective decisions: an interview with Matthew Segall, CEO of Optibrium. Interview by Wendy A. Warr
Matthew Segall
Drug Discovery Today
|
February 13, 2003
Smart high-throughput screening
Matthew Segall
Journal of Computer-Aided Molecular Design
|
December 14, 2011
Can we really do computer-aided drug design?
Matthew Segall
Expert Opinion on Drug Discovery
|
May 6, 2014
Advances in multiparameter optimization methods for de novo drug design
Matthew Segall
Journal of Computer-Aided Molecular Design
|
October 19, 2010
Making priors a priority
Matthew Segall, Andrew Chadwick
Future Medicinal Chemistry
|
June 8, 2011
The risks of subconscious biases in drug-discovery decision making
Matthew Segall, Andrew Chadwick
Drug Discovery Today
|
January 16, 2002
Early ADME/Tox studies and in silico screening
Albert P Li, Matthew Segall
Drug Discovery Today
|
February 23, 2019
Capturing and applying knowledge to guide compound optimisation
Matthew Segall, Tamsin Mansley, Peter Hunt, et al.
Future Medicinal Chemistry
|
January 19, 2017
Practical applications of matched series analysis: SAR transfer, binding mode suggestion and data point validation
Peter Hunt, Matthew Segall, Noel O'Boyle, et al.
Current Opinion in Drug Discovery & Development
|
February 26, 2004
In silico prediction of ADME properties: are we making progress?
Alan P Beresford, Matthew Segall, Michael H Tarbit
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Journal of Computer-Aided Molecular Design
|
January 13, 2011
Guiding effective decisions: an interview with Matthew Segall, CEO of Optibrium. Interview by Wendy A. Warr
Matthew Segall
Drug Discovery Today
|
February 13, 2003
Smart high-throughput screening
Matthew Segall
Journal of Computer-Aided Molecular Design
|
December 14, 2011
Can we really do computer-aided drug design?
Matthew Segall
Expert Opinion on Drug Discovery
|
May 6, 2014
Advances in multiparameter optimization methods for de novo drug design
Matthew Segall
Journal of Computer-Aided Molecular Design
|
October 19, 2010
Making priors a priority
Matthew Segall, Andrew Chadwick
Future Medicinal Chemistry
|
June 8, 2011
The risks of subconscious biases in drug-discovery decision making
Matthew Segall, Andrew Chadwick
Drug Discovery Today
|
January 16, 2002
Early ADME/Tox studies and in silico screening
Albert P Li, Matthew Segall
Drug Discovery Today
|
February 23, 2019
Capturing and applying knowledge to guide compound optimisation
Matthew Segall, Tamsin Mansley, Peter Hunt, et al.
Future Medicinal Chemistry
|
January 19, 2017
Practical applications of matched series analysis: SAR transfer, binding mode suggestion and data point validation
Peter Hunt, Matthew Segall, Noel O'Boyle, et al.
Current Opinion in Drug Discovery & Development
|
February 26, 2004
In silico prediction of ADME properties: are we making progress?
Alan P Beresford, Matthew Segall, Michael H Tarbit
Page
of 2